Compare Franklin Resources, Inc. (BEN) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Franklin Resources, Inc. vs GSK plc — how do they compare? Franklin Resources, Inc. trades at $33.37 (market cap $16.95B), while GSK plc trades at $50.33 (market cap $102.60B). The key difference: GSK plc is far larger — about 6.1× Franklin Resources, Inc.'s market cap, and Franklin Resources, Inc. pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BEN | GSK | |
|---|---|---|
Market Cap | $16.95B | $102.60B |
Sector | Financials | Health |
52-Week High | $35.77 | $61.18 |
52-Week Low | $21.18 | $38.22 |
Enterprise Value | $29.90B | $123.04B |
Dividend Yield | 3.96% | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Franklin Resources (BEN) trades at $33.59, up 0.21% on the day, with a bullish technical signal and consistent earnings beats. The company reported record AUM of $1.80 trillion as of July 31, 2026 (Business Wire, 2026-08-05), driven by strong inflows and diversification. Fundamentals show revenue growth to $8.77B in 2025 and a net income margin of 5.98%, though ROE remains low at 1.34%.
The outlook is positive with a consensus price target of $36.50 (22 analysts, August 2026) and recent momentum from private markets expansion. Key risks include volatile cash flows, with a net cash outflow of $835M in 2025, and competitive fee pressures. The stock offers upside potential but requires monitoring of margin sustainability and market-sensitive AUM growth.
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Franklin Resources, Inc.
Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
